A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

The first cohort included 36,082 GLP-1 receptor agonist users (dulaglutide [Trulicity], exenatide, liraglutide [Victoza], lixisenatide, and semaglutide) and 234,028 DPP-4 inhibitor users ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Dr. Troy Mensen is a family medicine doctor based in the Chicago area. He completed his undergraduate degree at the University of Northern Iowa and his doctorate at Des Moines University College ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

The increasingly popular obesity and diabetes drugs known as glucagon-like peptide-1 receptor agonists do not seem to worsen suicidality despite previous concerns, according to recent data ...

Objective Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...